1M6MYTD1Y5YMAX
Loading quotes...
Forecast
| Buy |
3 |
| Hold |
0 |
| Sell |
0 |
News Go to news feed
AIM ImmunoTech reports Q3 result: EPS improves to -1.57 USD
AIM ImmunoTech published figures for the quarter ended Sept. 30, 2025, with earnings per share (EPS) of -1.57 USD versus -6.00 USD in the prior year. Revenue was 0.0 million USD, down 25 percent from the year-ago quarter. The report contains no further operational details or outlook. » More on finanzen.net
Financials
| (EUR) | Jun 2026 | |
|---|---|---|
| Revenue | 22.78k | 7,41% |
| Gross profit | 18.40k | 44,59% |
| Net profit | −3.32m | 40,02% |
| EBITDA | −3.02m | 37,53% |
Fundamentals
| Metric | Value |
|---|---|
Market capitalization | 740.45k€ |
Number of shares | 3.40m |
52-week high/low | 2,48€ - 0,16€ |
| Dividends | No |
Beta | 1,19 |
P/E ratio | −0,07 |
PEG ratio | 0,00 |
P/B ratio | 0,56 |
P/S ratio | 9,08 |
Company profile
| Name | AIM ImmunoTech |
| CEO | Thomas K. Equels |
| Employees | 19 |
Discover assets
Shareholders of AIM ImmunoTech also invest in the following assets
